Biomarker ID | 38 |
PMID | 12507908 |
Year | 2003 |
Biomarker | Annexin 1 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated in Metastatic hormone refractory PCa (2.23 fold) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Formyl peptide interaction with formyl peptide receptors,Corticosteroids and cardioprotection,Prostaglandin biosynthesis and regulation,Integrated breast cancer pathway,EGFR1 pathway |
Experiment | Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer |
Type of Biomarker | Prognostic |
Cohort | 20 patients with late stage Prostate Cancer (Hormone Refactory) and 16 with early stage (Hormone Naive) and 21 non cancerous samples were chosen for the study. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | cDNA Microarray |
Clinical | No |
Remarks | Only Annexin 1 and 4 showed significant downregulation in early stage samples as compared to the benign samples. Annexins 1,2,4,6,7,8,11,13 were all tested for differential expression and 6,8,13 were not found to be differentially expressed |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | ANXA1 |